Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “C-met Overexpression”

4 trials

Showing 4 of 4 results

Testing effectiveness (Phase 2)Study completedNCT01892527
What this trial is testing

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Who this might be right for
Colorectal Cancer MetastaticC-met Overexpression
Armando Santoro, MD 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT03539536
What this trial is testing

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AbbVie 270
Early research (Phase 1)Study completedNCT01472016
What this trial is testing

Study of ABT-700 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
AbbVie (prior sponsor, Abbott) 74
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07323641
What this trial is testing

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center 60

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation